Lesiones orales y maxilofaciales en COVID 19 del Hospital de Mosul en Irak: estudio epidemiológico y enfoque de clasificación y tratamiento

Autores/as

DOI:

https://doi.org/10.17126/joralres.2021.069

Resumen

Durante la pandemia de COVID-19, muchas manifestaciones de la enfermedad aparecen en las regiones oral, perioral y maxilofacial, ya sea relacionadas con el propio virus o con los fármacos utilizados en el tratamiento. Objetivo: Este estudio tiene como objetivo identificar las lesiones orales y periorales más comunes en pacientes hospitalizados con COVID-19 en la ciudad de Mosul y su manejo; y también evaluar la incidencia y prevalencia de estas lesiones. Material y Métodos: Estudio prospectivo que incluyó a 338 pacientes (138 mujeres, 200 hombres) que tenían resultados positivos de PCR para SARS-CoV-2, con manifestaciones orales. Todos los datos se analizaron tomando las medias, frecuencias y porcentaje. Resultados: Las lesiones más frecuentes fueron las coloreadas (31%) y la estomatalgia (27%). La combinación de trastorno oral más común y comorbilidad previa fue la estomatalgia en pacientes con antecedentes de hipertensión. Las enfermedades sistémicas asociadas más comunes fueron la diabetes mellitus (19%) seguida de la hipertensión (17%). Las lesiones maculares tuvieron una mayor respuesta a los fármacos (40%) seguidas de la estomatalgia (28%), en comparación con las lesiones necróticas (0%). El tratamiento de las lesiones orales incluyó intervenciones quirúrgicas (26%) y tratamiento médico convencional (74%). Conclusión: Los trastornos bucales y periorales durante el COVID-19 son tran-sitorios; se necesita más evidencia para abordar de manera eficiente estas comorbilidades a corto plazo.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

[1]. Gironi LC, Boggio P, Giorgione R, Esposto E, Tarantino V, Damiani G, Savoia P. The impact of COVID-19 pandemics on dermatologic surgery: real-life data from the Italian Red-Zone. J Dermatolog Treat. 2020:1-7.

[2]. Pacifico A, Ardigò M, Frascione P, Damiani G, Morrone A. Phototherapeutic approach to dermatology patients during the 2019 coronavirus pandemic: real-life data from the Italian red zone. Br J Dermatol. 2020;183(2):375-6.

[3]. Cinelli E, Fabbrocini G, Fattore D, Marasca C, Damiani G, Annunziata MC. Safe distance, safe patients! Therapeutic management of oncological patients affected by cutaneous and mucosal adverse events during the COVID-19 pandemic: an Italian experience. Support Care Cancer. 2020;28(9):3991-3993.

[4]. Cristaudo A, Pigliacelli F, Pacifico A, Damiani G, Iacovelli P, Morrone A. Teledermatology and hygiene practices during the COVID-19 pandemic. Contact Dermatitis. 2020;83(6):536.

[5]. Damiani G, Gironi LC, Kridin K, Pacifico A, Buja A, Bragazzi NL, Spalkowska M, Pigatto PDM, Santus P; Young Dermatologists Italian Network, Savoia P. Mask-induced Koebner phenomenon and its clinical phenotypes: A multicenter, real-life study focusing on 873 dermatological consultations during COVID-19 pandemics. Dermatol Ther. 2021;34(2):e14823.

[6]. Giovanni Damiani, Laura C. Gironi, Ayman Grada, Khalaf Kridin, Renata Finelli, Alessandra Buja, Nicola L. Bragazzi, Paolo D. M. Pigatto, Paola Savoia, COVID-19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi-center, real-life, telemedical, and observational prospective study First published: 03 February 2021.

[7]. Damiani G Gironi LC , Pacifico A , Cristaudo A , Malagoli P , Allocco F , Bragazzi NL , Linder DM , Santus P , Buja A , Savoia P , Pigatto PD , COVID-19 Dermatologic Italian Task Force, Young Dermatologists Italian Network , Italian Journal of Dermatology and Venereology, 01 Apr 2021, 156(2):220-225.

[8]. Laura Cristina Gironi, Giovanni Damiani, Elisa Zavattaro, Alessia Pacifico, Pierachille Santus, Paolo Daniele Maria Pigatto, Ottavio Cremona, Paola Savoia Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses, first published: 22 December 2020.

[9]. Macha MJ, Boonyang U, Cazalbou S, Ben-Nissan B, Charvillat C, Oktar FN, David Grossin D. Comparative study of Coral Conversion, Part 2: Microstructural evolution of calcium phosphate. J Aust Ceram Soc 2015; 51:149–59.

[10]. Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, Li PH, Tan SY, Chang Q, Xie JP, Liu XQ, Xu J, Li DX, Yuen KY, Peiris, Guan Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003 ;362(9393):1353-8.

[11]. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207.

[12]. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(1):9.

[13]. Yoon JG, Yoon J, Song JY, Yoon SY, Lim CS, Seong H, Noh JY, Cheong HJ, Kim WJ. Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva. J Korean Med Sci. 2020;35(20):e195.

[14]. Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016;3(1):237-61.

[15]. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020.

[16]. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8.

[17]. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7).

[18]. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7.

[19]. Badran Z, Gaudin A, Struillou X, Amador G, Soueidan A. Periodontal pockets: A potential reservoir for SARS-CoV-2? Med Hypotheses. 2020; 143:109907.

[20]. Li Y, Ren B, Peng X, Hu T, Li J, Gong T, et al. Saliva is a non-negligible factor in the spread of COVID-19. Mol Oral Microbiol. 2020;35(4):141-5.

[21]. Baghizadeh Fini M. Oral saliva and COVID-19. Oral Oncol. 2020; 108:104821.

[22]. Anschau V, Sanjuan R. Fibrinogen Gamma Chain Promotes Aggregation of Vesicular Stomatitis Virus in Saliva. Viruses. 2020;12(3).

[23]. Siqueira WL, Moffa EB, Mussi MC, Machado MA. Zika virus infection spread through saliva--a truth or myth? Braz Oral Res. 2016;30.

[24]. Meng L, Hua F, Bian Z. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. J Dent Res. 2020;99(5):481-7.

[25]. To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM, et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin Infect Dis. 2020;71(15):841-3.

[26]. Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Investig. 2020;24(4):1619-21.

[27]. HL. G. Oral manifestations of systemic disease. Gen Dent 2017;65(6):23-9.

[28]. Galvan Casas C, Catala A, Carretero Hernandez G, Rodriguez-Jimenez P, Fernandez-Nieto D, Rodriguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-7.

[29]. Vieira AR. Oral manifestations in coronavirus disease 2019 (COVID-19). Oral Diseases. 2020; 00:1:1.

[30]. Chen L ZJ, Peng J, Li X, Deng X, Geng Z, et al. Detection of 2019-nCoV in Saliva and Characterization of Oral Symptoms in COVID-19 Patients. Available at SSRN 3556665. 2020.

[31]. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266-75.

[32]. Corchuelo J, Ulloa FC. Oral manifestations in a patient with a history of asymptomatic COVID-19: Case report. Int J Infect Dis. 2020; 100:154-7.

[33]. Santosh ABR, Muddana K. Viral infections of oral cavity. J Family Med Prim Care. 2020;9(1):36-42.

[34]. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, Jané-Salas E, Somacarrera Pérez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021;27 Suppl 3:710-712.

[35]. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2020.

[36]. Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated with COVID-19. Cureus. 2020;12(9): e10726.

[37]. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. Available at: https://www.cdc.gov/vaccines/covid-19/info-by-product/clini-cal-considerations.html.

[38]. United States Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19). Help stop the spread of COVID-19 in children. Ways to protect children from getting and spreading COVID-19. Available at: www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/children/protect-children.html.

[39]. FDA. Emergency Use Authorization (EUA). Pfizer-BioNTech COVID-19 Vaccine/BNT162b2. Available at: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine.

[40]. Emergency Use Authorization (EUA). Moderna COVID-19 Vaccine/mRNA-1273. Available at: https://www.fda.gov/emer-gency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine.

[41]. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317.

[42]. Jose RJM, A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respiratory Med 2020; 8, e46–e7.

[43]. Ding Tea. A Multi-Hospital Study in Wuhan, China: Protective Effects of Non-menopause and Female Hormones on SARS-CoV-2 infection. medrxiv202.

[44]. Flanagan KL, Fink AL, Plebanski, M, Klein SL. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annu Rev Cell Dev Biol 2017; 33:577–99

[45]. Klein SLF, K L. Sex differences in immune responses. Nat Rev Immunol 2016; 16:626–38.

[46]. Abdullah Mea. Gender effect on in vitro lymphocyte subset levels of healthy individuals. Cell Immunol 2012; 272:214–9.

[47]. Mori Mea. Sex Differences in Antiretroviral Therapy Initiation in Pediatric HIV Infection. PLoS One. 2015;10: e0131591.

[48]. Voigt EAea. Sex differences in older adults’ immune responses to seasonal influenza vaccination. Front Immunol. 2019; 10:180.

[49]. Webb Kea. Sex and pubertal differences in the type 1 interferon pathway associate with both X chromosome number and serum sex hormone concentration. Front Immunol 2019; 10:3167.

[50]. Ziegler SMA. Human Immunodeficiency Virus 1 and Type I Interferons—Where Sex Makes a Difference. Front Immunol 2017; 8:1224.

[51]. Farshidfar N, Hamedani S. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva. Oral Dis. 2020.

[52]. Marlus da Silva Pedrosa CRS, Fernando Neves Nogueira. Salivary Glands, Saliva and Oral Presentations in COVID-19 infection. short communication. 2020.

[53]. Dziedzic A WR. The impact of coronavirus infectious disease 19 (COVID-19) on oral health. Oral Dis 2020.

[54]. Putra BE, Adiarto S, Dewayanti SR, Juzar DA. Viral exanthem with "Spins and needles sensation" on extremities of a COVID-19 patient: A self-reported case from an Indonesian medical frontliner. Int J Infect Dis. 2020;96:355-8.

[55]. Picciani BLS, Santos LR, Teixeira-Souza T, Dick TNA, Carneiro S, Pinto JMN, Avelleira JCR, Azulay DR, Luiz RR, de Sousa Gonzaga HF. Geographic tongue severity index: A new and clinical scoring system. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;129(4):330-8.

[56]. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti A, Agarwal R. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. 2021;186(2):289-98.

[57]. Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, Simeo R, Buselli A, Rizzo D, Bussu F, Rubino S, Terragni P. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020:1–6.

[58]. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.

[59]. Elmas OF, Demirbas A, Tursen U, Atasoy M, Lotti T. Pemphigus and COVID-19: Critical overview of management with a focus on treatment choice. Dermatol Ther. 2020;33(6): e14265.

[60]. Ghalamkarpour F, Pourani MR. Aggressive course of pemphigus vulgaris following COVID-19 infection. Dermatol Ther. 2020;33(6): e14398.

[61]. Fisher J, Monette DL, Patel KR, Kelley BP, Kennedy M. COVID-19 associated parotitis. Am J Emerg Med. 2021; 39:254 e1- e3.

[62]. Bénézit F, Le Turnier P, Declerck C, Paillé C, Revest M, Dubée V, Tattevin P; RAN COVID Study Group. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. Lancet Infect Dis. 2020;20(9):1014-1015.

[63]. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Afia F, Distinguin L, Chekkoury-Idrissi Y, Hans S, Delgado IL, Calvo-Henriquez C, Lavigne P, Falanga C, Barillari MR, Cammaroto G, Khalife M, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Edjlali M, Carlier R, Ris L, Lovato A, De Filippis C, Coppee F, Fakhry N, Ayad T, Saussez S. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251-61.

[64]. Stern R AA, Sugahara KN. 2006; Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006; 85:699–715.

[65]. Damiani G, Pacifico A, Pelloni F, Iorizzo M. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated? J Eur Acad Dermatol Venereol. 2021;35(10):e645-e647

[66]. Kridin K, Schonmann Y, Tzur Bitan D, Damiani G, Peretz A, Weinstein O, Cohen AD. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study. Am J Clin Dermatol. 2021;22(5):709-718.

[67]. Pacifico A, d'Arino A, Pigatto PDM, Malagoli P, Young Dermatologists Italian Network, Damiani G. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast. Clin Exp Dermatol. 2021;46(7):1344-6.

[68]. Bragazzi NL, Riccò M, Pacifico A, Malagoli P, Kridin K, Pigatto P, Damiani G. COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration. Dermatol Ther. 2020;33(4):e13508.

Publicado

2021-12-31

Cómo citar

1.
Naser AI, Al-Sarraj MN, Deleme ZH. Lesiones orales y maxilofaciales en COVID 19 del Hospital de Mosul en Irak: estudio epidemiológico y enfoque de clasificación y tratamiento. J Oral Res [Internet]. 31 de diciembre de 2021 [citado 12 de junio de 2024];10(6):1-14. Disponible en: https://revistas.udec.cl/index.php/journal_of_oral_research/article/view/8680